14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
AVDL vs LFCR: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, Avadel Pharmaceuticals plc Ordinary Share (AVDL) captures the overall head-to-head institutional edge over Lifecore Biomedical, Inc. (LFCR) on higher Unified Composite conviction (62.9/100 BUY vs. 58.2/100 HOLD) after splitting the core matrix 8–2 (led by Growth & Scale, Profitability & Quality), while LFCR wins 4–2 across the 6-pillar growth and valuation breakdown. AVDL trades at $21.64 (28.8x Forward P/E, 2.5% operating margin) versus LFCR at $6.39 (8.7x Forward P/E, -6.2% operating margin).
Growth vs. Quality Trade-Off: AVDL earns the overall head-to-head edge with a stronger Unified Composite Score (62.9/100 BUY vs. LFCR 58.2/100 HOLD) and 0.14β · 2% Vol risk profile, whereas LFCR leads top-line expansion (-18.6% YoY revenue growth, 2.66x PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AVDL vs LFCR. Trailing 12-month operating profitability (AVDL 2.5% vs LFCR -6.2%) and valuation multiples (AVDL 28.8x vs LFCR 8.7x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Drug Manufacturers - Specialty & Generic value chain with $241.5M market capitalization and -6.2% operating margin.
OpEx & R&D Reinvestment33.7% of Rev ($36M)
90D Engineering Disclosures0 Published
Investor FAQ AVDL vs LFCR Key Questions & Quantitative Answers
As of Nov 20, 2026, Avadel Pharmaceuticals plc Ordinary Share (AVDL) captures the overall head-to-head institutional edge over Lifecore Biomedical, Inc. (LFCR) on higher Unified Composite conviction (62.9/100 BUY vs. 58.2/100 HOLD) after splitting the core matrix 8–2 (led by Growth & Scale, Profitability & Quality), while LFCR wins 4–2 across the 6-pillar growth and valuation breakdown. AVDL trades at $21.64 (28.8x Forward P/E, 2.5% operating margin) versus LFCR at $6.39 (8.7x Forward P/E, -6.2% operating margin). Growth vs. Quality Trade-Off: AVDL earns the overall head-to-head edge with a stronger Unified Composite Score (62.9/100 BUY vs. LFCR 58.2/100 HOLD) and 0.14β · 2% Vol risk profile, whereas LFCR leads top-line expansion (-18.6% YoY revenue growth, 2.66x PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates.
AVDL leads the Growth & Scale pillar: AVDL posts +54.9% YoY revenue growth and +0.0% YoY earnings growth on $249M TTM revenue (94.9% gross margin, 2.5% operating margin), compared with LFCR at -18.6% YoY revenue growth and +0.0% YoY earnings growth on $106M TTM revenue (27.5% gross margin, -6.2% operating margin). On trailing 12-month operating scale, AVDL generates $249M in USD-normalized revenue versus $106M for LFCR. In operating R&D and SG&A reinvestment, AVDL deploys N/A (0 90-day corporate R&D disclosures) versus 33.7% of Rev ($36M) (0 disclosures) for LFCR.
LFCR screens cheaper on headline valuation multiples. AVDL trades at 28.8x Forward P/E, 16.8x Trailing P/E, 0.07x PEG, and 8.5x EV/Revenue (1.1% EBITDA margin), whereas LFCR trades at 8.7x Forward P/E, 8.7x Trailing P/E, 2.66x PEG, and 3.6x EV/Revenue (6.5% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AVDL (-0.3% ROE) versus LFCR (-76.4% ROE) capital efficiency.
In options market volatility and institutional positioning, AVDL carries 2.4% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.14β · 2% Vol realized risk). By comparison, LFCR carries 0.0% implied volatility (<1st %ile, Compressed (<25th %ile)), a 0.77x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (0.44β · 9% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.